Manchester, UK-based drug discovery and development company C4X Discovery has appointed Clive Dix as its new chief executive officer.
Dix will take on his new role immediately, relinquishing his previous role as the firm’s executive chairman.
He joined C4X Discovery in 2014 as non-executive chairman, bringing over 30 years of experience in the pharmaceutical and biotechnology industries to the firm.
Since joining GlaxoSmithKline’s research department in 1988, Dix has held a series of senior leadership positions including chief executive officer of Convergence Pharmaceuticals and chairman of both Crescendo Biologics and Modern Biosciences.
In addition to his new role at C4X Discovery, Dix also serves as chairman of Calchan Limited, Centauri Therapeutics and Touchlight Genetics.
Dix said: “Having seen from an executive position the potential of the platform to generate entirely new compounds against high-value therapeutic targets more rapidly and efficiently than any technology I’ve come across before and having witnessed the interest we’re receiving in C4X Discovery, I am delighted to take the helm on a full-time basis.
“I have never been more excited by a company than this one.”